ZIMLAB Zim Laboratories Q3 FY26 results (Oct–Dec 2025) and concall
Zim Laboratories reported improved Q3 FY26 performance with operating income of INR 1,087 million and an EBITDA margin of 13.4%, driven by strong export growth and nutraceutical recovery. The company is actively addressing EU-GMP remediation, with the audit expected in Q1 FY27, and has made strategic investments of INR 35 crores to enhance long-term growth. Despite these efforts, investor concerns were voiced regarding the preferential issue pricing and the timeline for full commercialization in regulated markets.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 13.0%, net profit down 2.1% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 90 | 95 | 109 | 71 | 88 −1% | 108 +13% |
| EBITDA | 8 | 12 | 15 | 4 | 6 −26% | 13 +6% |
| Net profit | 1 | 4 | 5 | -2 | 0 −90% | 4 −2% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
